Johnson & Johnson is not going down without a fight after suffering a stinging $417 million talc powder defeat last month.
In a biosimilars case with blockbuster implications, Pfizer sued J&J, calling its strategy for fighting off Remicade biosimilars "anticompetitive.…
After years of going it alone in investigating opioid drugmakers, attorneys general across the U.S. are joining forces to drill into painkiller marketing…
A Nevada judge denied the drug industry's request for an injunction that would have stopped a new pricing-disclosure law in its tracks.
Infamous pharma exec Martin Shkreli’s social media posts have finally landed him in jail.
Lawmakers in California have approved a pricing transparency bill strongly opposed by PhRMA, sending it to Gov. Jerry Brown for a decision.
Mylan called Allergan's Restasis licensing agreement "desperate" and a "transparent" delay tactic in a federal court filing.
Seeking to shield itself against a “double jeopardy” of IP challenges, Allergan has transferred key Restasis patents to the Saint Regis Mohawk Tribe.
Eli Lilly has faced no shortage of trouble in diabetes recently, but the company now faces a new threat from rival Sanofi.
French drugmaker Servier, 14 people and the country’s drug regulator face new charges over marketing of a diabetes drug Mediator.